Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy.
We report on a 44-year-old woman affected by dermatopolymyositis resistant to conventional therapies who experienced long-term clinical improvement and remission after treatment with intravenous polyvalent immunoglobulin in a weekly schedule followed by rituximab therapy.
Sánchez-Ramón
Silvia
S
Department of Immunology, Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo, 46, 28007, Madrid, Spain. ssanchez.hgugm@salud.madrid.org
Ravell
Juan Carlos
JC
de la Torre
Inmaculada
I
Montoro
María
M
Rodríguez-Mahou
Margarita
M
Carreño-Pérez
Luis
L
Fernández-Cruz
Eduardo
E
López-Longo
Francisco Javier
FJ
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D003882:Dermatomyositis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000276:immunology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage; D007165:Immunosuppression Therapy / Q000379:methods; D018482:Muscle, Skeletal / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab; D012867:Skin / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D013995:Time; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab